EpiVax will be joining more than 1,400 companies from over 45 countries at Bio-Europe Spring, the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in Europe’s most innovative biopharma clusters. Partner with us to hear about our new immunoinformatics platform accelerating the advancement of personalized cancer vaccine design.
- $5.2 Million Department of Defense Grant to “Vaccine on Demand” Consortium
- 4th Computational Vaccinology Workshop at ISV
- About Us
- Business Development Representative
- EpiVax to Advance Development of Vaccine Against Stealth Flu Virus with New NIH-SBIR Funding
- Immune Engineering
- Immunogenicity Screening
- Lab-Based Services Overview
- Sample Page
- Vaccine Design & Redesign
Business InquiriesEpiVax, Inc.
146 Clifford St.
Providence, RI 02903